Overview of Sertralin Actavis

This section provides a clear, concise definition of Sertralin Actavis, detailing its composition, classification, and general function without discussing specific dosages, instructions, or side effects.

Property	Description
Active ingredient	Sertraline (as Sertraline hydrochloride)
Form	Film-coated tablets, scored
Pharmacological class	Antidepressant
Mechanism group	Selective Serotonin Reuptake Inhibitor (SSRI)
Origin	Synthetic compound

Defining Sertralin Actavis: Composition and Class

Sertralin Actavis is a prescription-only pharmaceutical preparation that contains the active ingredient Sertraline, which functions as a psychotropic agent. It is supplied for oral administration in the form of film-coated tablets. This medication is a single-component product and is fundamentally a synthetic compound, distinguishing it from preparations of natural origin. A distinctive feature of the Actavis brand's tablet is its biconvex, capsule shape and the inclusion of a score line, which confirms its design for precise division if needed.

Sertralin Actavis: A Selective Serotonin Reuptake Inhibitor (SSRI)

The medication is specifically classified as an antidepressant and belongs to the Selective Serotonin Reuptake Inhibitor (SSRI) group. This designation highlights the drug’s highly targeted action within the central nervous system. The active ingredient, Sertraline, works by selectively blocking the process, known as reuptake, where nerve cells normally recycle the neurotransmitter serotonin. By inhibiting this reabsorption, the drug enhances serotonergic neurotransmission. This pharmacological mechanism serves as the foundation for the drug's role in helping to restore a more functional chemical balance.

General Purpose: Supporting Mood and Emotional Stability

The overall therapeutic purpose of Sertralin Actavis is directly tied to its ability to modulate key brain chemistry, helping to restore stability and normalize neural function related to affective states. This modulation is utilized to help support mood and emotional regulation, acting as a pharmacological foundation for managing challenging states characterized by emotional instability. This aligns with the medicine's general aim to help stabilize the brain's emotional baseline, supporting mental health-related quality of life and the reduction of symptoms related to anxiety.

Regulatory References

NIH, StatPearls

What side effects are possible with Sertralin Actavis?

Possible Side Effects and Safety Information

Sertralin Actavis's safety profile is formally classified by regulatory documents, which group possible adverse reactions by frequency and affected body system. The regulatory framework uses terms such as Very Common (affecting more than 1 in 10 people) and Common (affecting up to 1 in 10 people) to describe the likelihood of effects.

Adverse Reaction Classification (Selected)

Classification	System-Organ Class	Examples of Documented Effects
Very Common	Gastrointestinal, Nervous System	Nausea, Dry mouth, Insomnia, Headache, Diarrhea
Common	Psychiatric, Gastrointestinal, Reproductive	Anxiety, Decreased appetite, Constipation, Ejaculation failure, Fatigue

Serious Adverse Reactions and Key Safety Notes

Official labeling documents certain serious risks. The FDA prescribing information includes a Boxed Warning regarding the risk of suicidal thoughts and behavior, particularly relevant in pediatric patients and young adults (up to 24 years old), and most critical at the initiation of treatment or following dose changes.

Another critical safety concern is the risk of Serotonin Syndrome, a potentially life-threatening condition; consequently, the medicine is contraindicated (absolutely restricted) for use with Monoamine Oxidase Inhibitors (MAOIs). Additionally, potential for Hyponatraemia (low blood sodium) is documented, with particular caution noted for the older adult population.

Upon stopping the medicine, individuals may experience discontinuation symptoms, officially listed as effects such as dizziness and sensory disturbances. Specific safety notes also apply to patients with hepatic impairment, where reduced clearance of the active ingredient may occur.

Overdose and Emergency Response

Overdose and when to seek help

The primary danger associated with Sertralin Actavis overdose is the risk of Serotonin Syndrome, along with other symptoms mediated by excessive serotonin activity. Immediate medical attention is required for any suspected overdose, and you should contact emergency services, a healthcare practitioner, or a regional Poison Control Centre immediately, even if you have no symptoms.

Documented Overdose Presentations

Symptoms of an overdose are generally mild to moderate when the drug is taken alone. These documented presentations primarily involve the Central Nervous System (CNS) and Gastrointestinal (GI) system and may include somnolence, dizziness, tremor, tachycardia (rapid heart rate), agitation, and nausea and vomiting. Less frequently, coma has been reported.

Key Overdose Risks and Emergency Action

While Sertralin Actavis generally has a wide safety margin in overdose when ingested alone, fatalities have been reported. These serious outcomes occurred predominantly when sertraline was taken in combination with other drugs and/or alcohol.

Due to the potential severity of co-ingestion, any overdosage is treated aggressively in a medical setting. There is no specific antidote for sertraline. Treatment focuses on supportive and symptomatic care, including maintaining an airway and monitoring cardiac and other vital signs. Activated charcoal may be considered in some cases.

Therapeutic Uses of Sertralin Actavis

What Sertralin Actavis Treats: Main Uses and Benefits

Sertralin Actavis is primarily used to provide symptomatic relief and supportive management across several core therapeutic domains, helping patients cope more steadily with difficult or persistent episodes. The medication is commonly applied in clinical settings marked by heightened patient distress across key areas.

The therapeutic benefit is considered relevant for easing challenging manifestations across multiple conditions, including Major Depressive Disorder (MDD), Panic Disorder, Post-Traumatic Stress Disorder (PTSD), Social Anxiety Disorder (Social Phobia), and Premenstrual Dysphoric Disorder (PMDD). It also is commonly used to help with managing Obsessive-Compulsive Disorder (OCD) in both adults and pediatric patients.

The medication helps address symptom clusters that create noticeable interference with daily stability, providing support that helps ease the overall symptom burden. It may assist with maintaining a sense of stability when symptoms are more noticeable and contributes to improved comfort during episodes of heightened symptoms.

Quick Fact: Relief for Intrusive Thoughts

The medication is commonly used to help with managing the intrusive thoughts (obsessions) and repetitive behaviors (compulsions) that characterize Obsessive-Compulsive Disorder, providing support that helps ease the overall symptom burden.

Eligibility and Restrictions for Use

Who can and cannot use Sertralin Actavis? — Official Regulatory Information

Eligibility Scope

This section outlines the official rules governing the use of Sertralin Actavis (sertraline) based on regulatory documents.

Classification	Populations / Conditions
Use is Contraindicated	Patients with known hypersensitivity to sertraline or any excipients. Concomitant use with Monoamine Oxidase Inhibitors (MAOIs), including irreversible MAOIs (like selegiline) or reversible MAOIs (like moclobemide and the antibiotic linezolid). Concomitant use with the antipsychotic pimozide is strictly prohibited.
Use is Restricted	Pediatric patients (under 18 years): Use is limited to the treatment of Obsessive Compulsive Disorder (OCD) in children and adolescents aged 6–17 years. Use is not established for children under 6 years of age.
Use Requires Caution	Patients with hepatic impairment: a lower or less frequent dose must be used. Use is not recommended in cases of severe hepatic impairment due to limited data. Caution is also advised in older adults and individuals with a history of seizure disorders.
Pregnancy/Lactation	Pregnancy: Safety and risk must be considered. Third-trimester use has been associated with complications in the newborn. Lactation: Sertraline is present in breast milk; the risks and benefits must be weighed.

Official Eligibility Summary

The eligibility profile is defined by a narrow set of absolute contraindications, primarily the co-administration with MAOIs and pimozide, or in patients with known allergy to the drug. For all other populations, use is permitted but may be restricted by age (limiting use in children to OCD) or requires a cautious approach with dose adjustment, particularly in patients with liver disease.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Contraindicated Combinations

Sertralin Actavis must not be used concurrently with Monoamine Oxidase Inhibitors (MAOIs), including MAOI antidepressants (e.g., phenelzine, tranylcypromine, moclobemide), the antibiotic linezolid, or intravenous methylene blue, due to the substantial risk of serotonin syndrome. A minimum of 14 days must elapse between discontinuing a MAOI and starting Sertralin Actavis, and vice versa. Use with the antipsychotic pimozide is also contraindicated due to a resulting increase in pimozide plasma levels, which is associated with an elevated risk of serious QTc prolongation.

Other Clinically Significant Interactions

Serotonergic Agents: Co-administration with other medicines that enhance serotonergic neurotransmission (e.g., triptans, other SSRIs, fentanyl, tramadol, St. John's wort) requires caution and close monitoring for signs of serotonin syndrome.
Bleeding Risk: The risk of bleeding is increased when Sertralin Actavis is used alongside drugs that affect blood clotting, such as oral anticoagulants (e.g., warfarin), aspirin, and NSAIDs.
CYP2D6 Substrates: Sertraline is an inhibitor of the CYP2D6 enzyme. Dose reduction or monitoring may be required for other medicines that are primarily metabolized by CYP2D6.

Mechanism of Action

️ How Sertralin Actavis Works

Sertraline's action is defined by its influence on specific biochemical processes within the central nervous system. The mechanism is initiated by specific molecular interaction and proceeds through a time-dependent sequence of neural circuit changes.

Selective Serotonin Reuptake Inhibition

Sertraline acts as a selective inhibitor of the Serotonin Transporter (SERT) (SLC6A4), the protein responsible for clearing the neurotransmitter serotonin (5-HT) from the synaptic space. This blockade prevents reuptake, resulting in an immediate increase in the functional concentration of serotonin in the synaptic cleft. This molecular action initiates a sequence of downstream physiological events.

Time-Dependent Neural Adaptation and Functional Change

Acute elevation of serotonin is initially countered by the activation of endogenous feedback mechanisms, specifically the 5-HT1A autoreceptors. The full physiological effect requires a delayed process where these autoreceptors gradually desensitize and downregulate. This cellular desensitization eliminates the initial inhibitory constraint, enabling a sustained, functional increase in serotonin release. This systemic change results in long-term neuroplastic changes that establish a modified functional baseline within affected neural circuits.

Dosage and Administration Information

How to Use Sertralin Actavis

Sertralin Actavis is administered exclusively by the oral route, primarily available as film-coated tablets in strengths of 25 mg, 50 mg, and 100 mg. The required administration frequency is once daily across all approved adult uses. The tablets may be taken with or without food at any time of day.

Official Dosing Regimens

The initial dosage is dependent on the condition being addressed. For Major Depressive Disorder (MDD) and Obsessive-Compulsive Disorder (OCD), the starting dose is typically 50 mg once daily. For Panic Disorder, Post-Traumatic Stress Disorder (PTSD), and Social Anxiety Disorder, a lower initial dose of 25 mg once daily is used before increasing after one week. The maintenance range is generally 50 mg to 200 mg once daily, representing the maximum dose.

Administration and Adjustment Protocols

To achieve the maintenance dose, the dosage may be increased in increments of 25 mg or 50 mg. Due to the pharmacological half-life, these adjustments must occur at intervals of at least one week to allow for steady-state concentrations. The tablets are scored and can be divided if required for accurate dosing. When discontinuing treatment, the dose must be gradually reduced over a period.

Population-Specific Use

Specific dosage modifications are required for certain patient groups. For individuals with mild hepatic impairment, the recommended starting and maximum dosages are officially set at half the standard dose. For pediatric patients (ages 6 to 12) with OCD, the starting dosage is 25 mg once daily, increasing to 50 mg after one week.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Sertralin Actavis

This overview describes the types of clinical studies that have been conducted for Sertralin Actavis, focusing on the available research evidence base as reported in official scientific and regulatory sources. This section is strictly an overview of the research structure and does not offer clinical advice, dosing instructions, or safety information.

Evidence for Use in Major Depressive Disorder (MDD) and Obsessive-Compulsive Disorder (OCD)

Research exploring Sertralin Actavis for Major Depressive Disorder (MDD) was studied for using randomized controlled trials (RCTs), systematic reviews, and meta-analyses. These controlled trials were used in research exploring how symptoms change over time across patient groups, including adult outpatients and older adults. Longer-term prophylactic trials were conducted, tracking patients for up to 20 months to examine patterns related to the occurrence of depressive symptoms.

For Obsessive-Compulsive Disorder (OCD), research was studied for both adults and children/adolescents (ages 6 to 17 years). Studies exploring short-term symptom changes monitored the frequency and severity of obsessive and compulsive behaviors. While this research provides context for the drug's use in OCD, it is important to note that the established evidence profile for children and adolescents is primarily confined to this specific OCD indication.

Evidence for Use in Anxiety and Related Conditions

Research involving Sertralin Actavis was evaluated in studies addressing Panic Disorder, Social Anxiety Disorder (Social Phobia), and Premenstrual Dysphoric Disorder (PMDD). For Panic Disorder, controlled trials were used in research exploring how symptoms change over time, examining the frequency and intensity of panic symptoms. Regulatory sources describe the evidence base for this condition as having a comprehensive scope.

Studies for PMDD, a condition characterized by fluctuating or episodic manifestations, included randomized controlled crossover trials. Research examined symptom intensity and functional limitation, tracking patient-reported outcomes describing perceived discomfort across multiple menstrual cycles.

Evidence for Use in Post-Traumatic Stress Disorder (PTSD)

Research has studied Sertralin Actavis for Post-Traumatic Stress Disorder (PTSD) through multiple controlled trials, including those focusing on both acute symptom management and longer-term maintenance. Studies were conducted during periods of heightened symptom activity and monitored symptom severity. Data described in the studies reflect patterns related to symptom changes across acute phases lasting 10 to 12 weeks. However, findings were mixed and demonstrated that results may not be consistent across all study populations, such as military veterans with combat-related PTSD in certain settings.

Long-Term Research and Follow-up Durability

Long-term research was observed in trials that extend beyond the initial acute treatment phase to assess symptom occurrence over time. However, long-term effects are not fully established beyond the intermediate maintenance phase for certain conditions, and follow-up durations were limited in many acute studies. Research is ongoing in this area.

Key Studies & References

Sertraline (StatPearls)

Frequently Asked Questions (FAQ)

Common questions about Sertralin Actavis (FAQ)

Q: Is Sertralin Actavis the same as other sertraline brands?

A: Sertralin Actavis contains the active ingredient sertraline. Regulatory documents confirm that multiple products, including various brands and generic versions, are approved for use. These products are considered therapeutically equivalent, meaning they are expected to have the same clinical effect and safety profile.

Q: How quickly do people usually start noticing any changes from Sertralin Actavis?

A: Official product information indicates that clinical improvement may require a period of several weeks of use. The full therapeutic effect is not seen immediately. Regulatory documents advise that dose adjustments, if needed, should be separated by at least one week to allow the medicine to stabilize in the body.

Q: Is Sertralin Actavis considered a controlled substance?

A: No, according to official regulatory agencies, sertraline is generally not classified as a controlled substance in the United States or internationally. This classification reflects its scheduling status and does not comment on the potential for discontinuation symptoms.

Q: Is Sertralin Actavis addictive or habit-forming?

A: Regulatory sources generally do not associate sertraline with drug abuse or addiction liability. However, regulatory documents warn that sudden discontinuation can lead to withdrawal-like symptoms, also known as discontinuation syndrome. For this reason, official guidance requires the dose to be gradually reduced when treatment is stopped.

Q: What if I forget to take Sertralin Actavis for a day?

A: According to official patient information, if a dose is missed, it should be taken as soon as possible. If it is almost time for the next scheduled dose, the missed dose should be skipped entirely, and the regular schedule should be resumed. Regulatory guidance indicates that patients should avoid doubling the next dose.

Q: Is it okay to drive or operate machinery while using Sertralin Actavis?

A: Regulatory labeling includes warnings that this medicine can affect performance in activities requiring complex motor and mental skills. Official documents describe the need for caution when performing complex tasks like driving or operating heavy machinery, due to the potential for adverse effects.

Q: Does Sertralin Actavis have an expiry date mentioned in official documentation?

A: Yes. Regulatory guidelines require the medicine to be stored under specific conditions and confirm it has a determined shelf-life. Official information advises that patients should not keep outdated medicine or medicine no longer needed, confirming the importance of checking its expiry date.

Q: How long does the body take to fully adjust to Sertralin Actavis?

A: The time needed for the active ingredient to reach stable levels in the blood is defined by its pharmacokinetics profile. Based on the drug's average half-life, the medicine reaches steady-state plasma levels—meaning the amount entering equals the amount leaving—after approximately one week of once-daily dosing.

Q: What is the relationship between Sertralin Actavis and sexual side effects?

A: Official documentation lists reproductive system disorders as possible adverse reactions. Common examples found in regulatory safety data include ejaculation failure in men and decreased libido (reduced sexual desire) in both men and women.

Q: How is Sertralin Actavis generally eliminated from the body?

A: After being metabolized in the liver, the drug is eliminated primarily through two routes. Regulatory data shows that the body excretes approximately 40–45% of the drug through the urine and a similar amount through the feces, with little unchanged sertraline excreted in the urine.

Q: What is meant by 'pharmacokinetics' in relation to Sertralin Actavis?

A: Pharmacokinetics is the scientific term used in regulatory documents to describe how the body absorbs, distributes, metabolizes, and eliminates a drug. For Sertraline, the pharmacokinetics profile provides specific parameters such as the average terminal elimination half-life of about 26 hours.

Q: Does Sertralin Actavis affect blood pressure?

A: Changes in blood pressure are not typically listed as a common adverse reaction during routine use. However, regulatory safety warnings indicate that in rare or severe events, such as a drug overdose or Serotonin Syndrome, blood pressure changes, including hypertension (high) or hypotension (low), may occur.

Q: Are there official recommendations for monitoring while on Sertralin Actavis?

A: Official documentation describes the need for monitoring certain risks associated with treatment. This includes closely observing for the emergence of suicidal thoughts or behavior, especially at the start of treatment or following dose changes. Monitoring for signs of bleeding and Serotonin Syndrome is also recommended.

Q: What happens if Sertralin Actavis is taken with alcohol?

A: Regulatory information indicates that drinking alcoholic beverages should be avoided while taking sertraline, as this combination may increase certain adverse effects of the medicine, such as dizziness, drowsiness, confusion, and difficulty concentrating.

Q: Is a metallic taste common when first starting Sertralin Actavis?

A: Official adverse reaction lists do not always use the specific term 'metallic taste.' However, regulatory safety data includes taste perversion or taste disturbance as a possible side effect of the medicine.

Q: Is there a link between Sertralin Actavis and joint pain?

A: Official adverse reaction lists include possible musculoskeletal effects. Regulatory documents indicate that arthralgia (joint pain) and myalgia (muscle pain) have been reported as possible side effects, though the frequency is typically lower than common side effects.

Q: Is it common for people to report increased sweating while using Sertralin Actavis?

A: Official adverse reaction lists include the effect of increased sweating, also known as hyperhidrosis. Regulatory data indicates this is a possible side effect of the medicine, although it is generally less common than effects like nausea or headache.

Q: What research is available on the impact of Sertralin Actavis on cognitive function?

A: Studies reviewed by regulatory bodies suggest that sertraline does not typically impair the ability of healthy individuals to perform tasks requiring complex motor and mental skills in controlled laboratory settings. However, official warnings caution that individuals may still be affected adversely.

How should Sertralin Actavis be stored and disposed of?

How to Store and Dispose of Sertralin Actavis

Sertralin Actavis (sertraline hydrochloride) must be stored under specific environmental conditions to maintain its quality and efficacy, as required by regulatory authorities.

Official Storage Conditions

Temperature: Store at controlled room temperature, specifically between 20°C and 25°C (68°F and 77°F). Brief temperature excursions up to 30°C are permitted.
Container and Protection: The medication must be kept in its original container and the cap must remain tightly closed to protect it from moisture.
Child Safety: It is mandatory to keep this medicine out of the sight and reach of children.

Disposal of Unused Medicine

Unused or expired Sertralin Actavis must be disposed of safely. The medicine is not recommended for disposal by flushing down a toilet or sink. The product must be returned to a designated drug take-back program or a pharmacy for proper disposal. If a take-back program is unavailable, follow the official guidance for mixing the product with an unappealing substance, sealing it, and discarding it in household trash.

Sertralin Actavis